ccct2 | Pantai Hospital Kuala Lumpur
View All Active Trials

A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20)

Status

Active (Non-Recruiting)

Disease

HER2-negative breast cancer

Treament Agent

MK2870 vs Physician's Choice of Chemotherapy

Study Phase

Phase III

Physician Name(s)

Dr John Low Seng Hooi

Dr Mastura Md Yusof

Dr Malwinder Singh Sandhu

Description

This non-interventional, multicenter, retrospective study aims to estimate the prevalence, characteristics, treatment patterns, and outcomes of HER2-low metastatic breast cancer (mBC) by re-examining archived FFPE slides in patients previously classified as HER2-negative. The study includes patients from regions with limited data on HER2-low mBC, focusing on those with HER2-negative, locally advanced or metastatic disease who progressed on systemic therapies between January 2019 and December 2022, with at least 12 months of follow-up data. HR-positive patients who progressed within 24 months after adjuvant endocrine therapy are also eligible.

Cancer Type

Cervical Cancer

I would like to be a part of tomorrow's breakthrough

Clinical trials are part of research studies involving patient volunteers that are conducted to find safe and effective treatments for a variety of health conditions. They are critical to the advancement of medicine and improving patient health. Participating in clinical trials offers patients the opportunity to try new and effective treatments that could potentially improve their condition while taking part in vital research that can benefit many future patients.

In Pantai Hospital Kuala Lumpur, clinical trials are carried out under our Clinical Research team.

If you would like to participate in any of our clinical trials or would like to know, please provide your information below and we will be in touch with you: